Medexus Pharmaceuticals Inc. (TSX:MDP)
3.940
+0.070 (1.81%)
Apr 10, 2026, 4:00 PM EST
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $25.32M USD in the quarter ending December 31, 2025, a decrease of -15.56%. This brings the company's revenue in the last twelve months to $99.43M, down -9.23% year-over-year. In the fiscal year ending March 31, 2025, Medexus Pharmaceuticals had annual revenue of $108.33M, down -4.18%.
Revenue (ttm)
$99.43M
Revenue Growth
-9.23%
P/S Ratio
0.94
Revenue / Employee
$1.09M
Employees
91
Market Cap
127.88M CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 108.33M | -4.72M | -4.18% |
| Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
| Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
| Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
| Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ascend Wellness Holdings | 686.36M |
| Auxly Cannabis Group | 151.48M |
| Planet 13 Holdings | 141.74M |
| Cannara Biotech | 112.25M |
| Decibel Cannabis Company | 109.31M |
| HLS Therapeutics | 76.10M |
| Charlotte's Web Holdings | 68.41M |
| Vext Science | 66.63M |
Medexus Pharmaceuticals News
- 2 months ago - Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 2 months ago - Medexus Schedules Third Fiscal Quarter 2026 Conference Call - Newsfile Corp
- 5 months ago - Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares - Newsfile Corp
- 5 months ago - Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares - Newsfile Corp
- 5 months ago - Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 5 months ago - Medexus Schedules Second Fiscal Quarter 2026 Conference Call - Newsfile Corp
- 7 months ago - Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors - Newsfile Corp
- 8 months ago - Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection - Newsfile Corp